Teknova has launched Build-Tek, an AI-driven custom product configurator designed to streamline the creation of complex reagent requests for therapeutic and diagnostic developers. This platform, which evolved from Teknova’s proprietary configurator introduced in 2024, aims to simplify the transition from preclinical research to clinical manufacturing. In Q2, Teknova reported a record revenue of $12.2 million, with an 18% increase across various segments. The company also improved its financial outlook for 2026, raising revenue guidance to $45-47 million and reducing expected free cash outflow to under $8 million.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://pulse2.com/teknova-build-tek-ai-configures-complex-custom-reagents-in-minutes-as-biotech-manufacturing-platform-expands/
